Akebia holder plans sale of 67,658 shares

A shareholder of Akebia Therapeutics, Inc. filed a Rule 144 notice to sell 67,658 shares of common stock on the Nasdaq through Morgan Stanley Smith Barney LLC, for an aggregate market value of $94,349.

Rhea-AI Filing Summary

A shareholder of Akebia Therapeutics, Inc. filed a Rule 144 notice to sell 67,658 shares of common stock on the Nasdaq through Morgan Stanley Smith Barney LLC, for an aggregate market value of $94,349. These shares were acquired as restricted stock from Akebia on January 31, 2026, with payment dated February 2, 2026. The filing notes that 265,365,993 shares of the issuer’s common stock are outstanding.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the latest Akebia (AKBA) Rule 144 filing disclose?

The filing discloses a planned sale of 67,658 Akebia common shares under Rule 144. The shares, valued at $94,349, will be sold on Nasdaq through Morgan Stanley Smith Barney LLC and were acquired as restricted stock on January 31, 2026.

How many Akebia (AKBA) shares are planned for sale and at what value?

The notice covers a proposed sale of 67,658 common shares of Akebia Therapeutics. The filing lists an aggregate market value of $94,349.00 for these shares, indicating the approximate dollar amount involved in the transaction at the time of the notice.

On which exchange will the Akebia (AKBA) shares in this Rule 144 filing be sold?

The shares covered by this Rule 144 notice are to be sold on the Nasdaq stock market. The filing specifies Nasdaq as the securities exchange where the 67,658 Akebia common shares may be sold by the shareholder’s broker.

Who is the broker for the Akebia (AKBA) Rule 144 share sale?

The broker handling the planned sale is Morgan Stanley Smith Barney LLC. The filing lists its address as 1 New York Plaza, 38th Floor, New York, NY 10004, and shows it as the intermediary for selling the 67,658 Akebia shares.

When were the Akebia (AKBA) shares in this filing acquired and in what form?

The filing states the shares were acquired on January 31, 2026 as restricted stock from Akebia Therapeutics, Inc.. This indicates the securities were originally issued with transfer limitations before being eligible for resale under Rule 144.

How many Akebia (AKBA) common shares are outstanding according to this notice?

The notice reports that 265,365,993 common shares of Akebia Therapeutics are outstanding. This figure provides context for the company’s total equity base relative to the 67,658 shares covered by the Rule 144 resale notice.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/02/2026 - 05:55 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001619834
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Akebia Therapeutics, Inc.
SEC File Number	001-36352
Address of Issuer	245 FIRST STREET CAMBRIDGE MASSACHUSETTS 02142
Phone	617-871-2098
Name of Person for Whose Account the Securities are To Be Sold	Burke Steven Keith
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Morgan Stanley Smith Barney LLC 1 New York Plaza, 38th Floor New York NY 10004	67658	94349.00	265365993	02/02/2026	Nasdaq

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	01/31/2026	Restricted Stock	Akebia Therapeutics, Inc.			67658	02/02/2026	n/a

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks
Date of Notice	02/02/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	11/17/2023
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Carolyn M. Rucci, attorney-in-fact for Steven K. Burke
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)